Home › Funds › ABN AMRO INVESTMENT SOLUTIONS › VRTX

ABN AMRO INVESTMENT SOLUTIONS position in VRTX

VERTEX PHARMACEUTICALS INC · Health Care

ABN AMRO INVESTMENT SOLUTIONS reported holding 93,742 shares of VRTX (VERTEX PHARMACEUTICALS INC) in its Q3 2026 13F filing — a position valued at US$49.0M, representing 0.37% of its reported portfolio and ranking #50 among its reported holdings. ABN AMRO INVESTMENT SOLUTIONS has disclosed VRTX holdings in 13 of the last 13 reported quarters, going back to Q3 2023.

Latest position (Q3 2026)93.74K sh
Reported value held$49.01M
Portfolio Weight0.37%
First reportedQ3 2023
Last changeAdd
Updated2026-11-13

Last updated: 2026-11-13 · Source: SEC EDGAR Form 13F-HR

How ABN AMRO INVESTMENT SOLUTIONS's VRTX position evolved

ABN AMRO INVESTMENT SOLUTIONS first disclosed a stake in VRTX in Q3 2023 at 28,475 shares (US$9.9M). The position peaked in Q1 2025 at 137,642 shares, worth US$66.7M. Across 13 filings, ABN AMRO INVESTMENT SOLUTIONS increased the stake 4 time(s), trimmed it 8 time(s) and left it unchanged 0 time(s). The most recent filing (Q3 2026) shows 93,742 shares valued at US$49.0M — an increase of 9,111 shares quarter over quarter.. Notable position changes include a 1274% increase in Q4 2024 (shares rose 20% over the following quarter), a 85% trim in Q4 2025 (shares fell 1% over the following quarter), a 258% increase in Q1 2026 (shares rose 11% over the following quarter).

Quarter by quarter

QuarterSharesValueChange
Q3 2023 28.48K $9.90M New
Q4 2023 26.68K $10.86M Reduce
Q1 2024 15.73K $6.58M Reduce
Q2 2024 13.63K $6.39M Reduce
Q3 2024 10.20K $4.75M Reduce
Q4 2024 140.24K $56.47M Add
Q1 2025 137.64K $66.73M Reduce
Q2 2025 130.29K $58.01M Reduce
Q3 2025 125.96K $49.33M Reduce
Q4 2025 19.07K $8.65M Reduce
Q1 2026 68.22K $30.46M Add
Q2 2026 84.63K $42.04M Add
Q3 2026 93.74K $49.01M Add

Dots on the line are colored by change type; missing quarters mean no position was reported.

About VRTX and 13F data

VRTX (VERTEX PHARMACEUTICALS INC) is a Health Care company. 32 other funds we track also report a position in VRTX — the largest reported positions include Capital World Investors (US$13.58B), Capital World Investors (US$12.97B), Capital Research Global Investors (US$9.68B). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.

Other funds holding VRTX

All VRTX fund holders →

FAQ

How long has ABN AMRO INVESTMENT SOLUTIONS held VRTX?

ABN AMRO INVESTMENT SOLUTIONS has disclosed VRTX holdings in 13 of the last 13 reported quarters, going back to Q3 2023.

What is ABN AMRO INVESTMENT SOLUTIONS's current position in VRTX?

As of Q3 2026, ABN AMRO INVESTMENT SOLUTIONS holds 93.74K shares of VRTX (VERTEX PHARMACEUTICALS INC), valued at $49.01M, representing 0.37% of its reported portfolio and ranking #50.

Has ABN AMRO INVESTMENT SOLUTIONS been buying or selling VRTX?

In the latest 13F filing (Q3 2026), ABN AMRO INVESTMENT SOLUTIONS increased its position in VRTX. The position peaked in Q1 2025 at 137.64K shares.

Which other funds hold VRTX?

Other major institutional holders of VRTX include Capital World Investors, Capital World Investors, Capital Research Global Investors, among 32 funds with disclosed positions.

Where does this data come from?

All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.